



Company Overview & Vision

Martin Jönsson

CEO

AlzeCure Pharma

- Founded in **2016**, out of a research foundation sponsored by Alzheimerfonden
- **Experienced team** with extensive background within Pharma industry
- Based at Novum Science Park, **Karolinska Institute**, Stockholm, Sweden
- Working in **Alzheimer's Disease (AD)** and **Pain** – multi-billion markets / great unmet medical need
- Three project platforms with multiple candidates
 - **NeuroRestore®** - A novel first-in-class symptomatic treatment for cognitive disorders, e.g. AD
 - **Alzstatin®** – An innovative disease-modifying treatment for AD
 - **Painless** – Innovative projects for osteoarthritic and neuropathic pain
- Listed on **Nasdaq First North Premier Growth Market** since Nov. 2018 (Ticker: ALZCUR)
- Market cap: **SEK 326m** (Aug 30, 2021)
- Cash position: **SEK 78m** (Q2 2021 report)



Our Business Model

- We are a **Research & Development** company
- Research & **develop through early clinical phase** and then **out-license** our projects
- Gain incomes through:
 - **Upfront payments**
 - **Milestone payments**
 - **Royalties** on sold products



Small molecule drugs – AlzeCure's approach for increased success

DIFFERENCES BETWEEN SMALL MOLECULES & BIOLOGICS*

SMALL MOLECULE
DRUG

LARGE BIOLOGIC

AlzeCure focus



Small molecule drug



Monoclonal antibody
c. 25,000 atoms

Smaller molecules can have increased likelihood of
penetrating the Blood Brain Barrier

A pipeline of small-molecule programs

– Multiple candidates increase chance of success

Platform	Candidate	Indication	Research phase	Preclinical phase	Phase I	Phase II	Phase III
NeuroRestore®	ACD856	Alzheimer's Disease, Sleep disorders, Traumatic brain injuries Parkinson's disease				<i>Ongoing</i> Fully funded Ph I study	
	ACD857	Alzheimer's Disease					
Alzstatin®	ACD679	Alzheimer's Disease					
	ACD680	Alzheimer's Disease					
PainLess	ACD440	Neuropathic Pain				<i>Positive 1b read-out</i> Preparing for phase II filing	
	TrkA-NAM	Osteoarthritic Pain & other severe pain conditions					

Phase completed

Phase ongoing




Our primary Focus area

Alzheimer's Disease

- Costs the society more than **oncology and cardiovascular diseases** TOGETHER
- The patient population and costs will **TRIPLE** in the next 30 years



Tripling patient population – due to the aging population



- **50 million** people worldwide live with dementia ...
- ... and **doubling every 20 years**
- Alzheimer's accounts for 60 - 70% of all dementia cases

Alzheimer's Disease - Progressive & lethal disorder with lack of available therapies

Pre-symptomatic Alzheimer's
10 - 20 years prior to symptoms

Symptomatic Alzheimer's
7 - 10 years life expectancy



- In Pre-symptomatic Alzheimer's, **A β amyloid pathology & plack** is building up in the brain but there are no clinical symptoms
- There are no preventive treatments for this stage of Alzheimer's

- The stage includes **dying neurons in the brain** which leads to **speech problems, memory loss and dementia**, and symptoms start manifesting



Sales: > US\$ 2bn/year

No drugs available

Very few drugs available - *associated with low efficacy and severe side effects*


HUGE UNMET MEDICAL NEED IN BOTH CATEGORIES



Two Alzheimer's platforms - 1st-in-class properties & potential game-changers

TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED

Disease-modifying therapy



Alzstatin[®]

Targeting Amyloid Production

- Novel Oral Small Molecule

Symptomatic therapy



NeuroRestore[®]

Improving Neuronal Function

- Novel Oral Small Molecule

Our platform PAINLESS – Targeting unmet medical needs within pain



Neuropathic pain*

25 – 30 million patients

Project: ACD440



Osteoarthritis & severe pain conditions

> 300 million patients

Project: TrkA-NAM

Key investment highlights in AlzeCure



Targeting areas of **huge unmet medical needs**



Strong team with extensive experience and track record



Platforms with first-in-class properties and potential **game-changers**




Parallel investments in several candidates and potent **follow-up programs**



Multi-billion dollar market **opportunities**



Evolving into a **phase II company**

A composite image featuring a brain model, a neuron, and laboratory equipment. In the center, a pair of hands holds a realistic model of a human brain, with one hand showing the outer surface and the other showing a cross-section of the internal structures. To the left, a translucent blue neuron with multiple branching processes is superimposed over the background. The background is a blurred laboratory setting with various glassware and equipment.

Karolinska Institutet Novum Science Park
Hälsövägen 7, 141 57 Stockholm
SWEDEN

www.alzecurepharma.com

